Volume : 10, Issue : 11, November – 2023

Title:

CLINICAL IMPACT OF SEMAGLUTIDE ON OBESITY MANAGEMENT AMONG SAUDI ADULTS: A CROSS-SECTIONAL STUDY

Authors :

Ahmad A Baharith, Dr. Mahmood M. Sadagah, Mahdi Hassan Aldajani, Hussain Hassan Aldajani, Saadiah Adnan Balkhy , Abdulaziz Faris Alshehri, Meshal Hussain Alzahrani, Saeed Mohammed Alzahrani, Faisal Ahmed Alhejaily , Lujain Sameer Samarin, Omar Ahmed Bashanam, Abdulaziz Ahmed Alkathami, Zainab Aziz Al Sahwan, Sara Mohammad Altheebi and Hoda Jehad Abousada

Abstract :

Objective: To assess the clinical impact of semaglutide on obesity management among Saudi adults.
Methods: This study will employ a cross-sectional research design to assess the clinical impact of semaglutide on obesity management among Saudi adults. Cross-sectional studies allow for the collection of data at a single point in time, providing a snapshot of the prevalence and effectiveness of obesity management with semaglutide within the chosen population.
Results: The study included 359 participants. The most frequent gender among them was male (n= 216, 60.2%) followed by female (n= 143, 39.8%). The most frequent age among study participants was 29-39 years (n= 100, 27.9%) followed by 18-28 years (n= 97, 27%). Participants were asked if they used any type of semaglutide. There were 70 participants said yes (19.5%), and 289 participants said no (80.5%). The most frequent type of semaglutide the participants used was Ozempic (n= 55, 78.6%) followed by Saxenda (n= 8, 11.4%) and the least was Mounjaro (n= 3, 11.4%). The most frequent height among them was 1.61-1.70 m (n= 28, 40%) followed by 1.71-1.80 m (n= 18, 25.7). Participants were asked about their weight before taking medication and their weight now. The most frequent weight before taking medication was 76-85 kg (n= 76-85, 37.1%), and the most frequent weight now was 66-75 kg (n= 25, 35.7%).
Conclusion: Study results showed that most study participants are overweight according to their BMI. Most commonly don’t use any type of semaglutide. Most of them don’t have type 2 diabetes. In addition, most of study participants had good social connection.

Cite This Article:

Please cite this article in press Hoda Jehad Abousada et al, Clinical Impact Of Semaglutide On Obesity Management Among Saudi Adults: A Cross-Sectional Study., Indo Am. J. P. Sci, 2023; 10 (11).

Number of Downloads : 10

References:

1. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(3):254-266.
2. Ward ZJ, Bleich SN, Cradock AL, et al.. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440-2450.
3. Pantalone KM, Hobbs TM, Chagin KM, et al.. Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system. BMJ Open. 2017;7(11):e017583.
4. Waters H, Graf M. America’s Obesity Crisis: The Health and Economic Costs of Excess Weight. Milken Institute; 2018.
5. Bray GA, Ryan DH. Evidence-based weight loss interventions: individualized treatment options to maximize patient outcomes. Diabetes Obes Metab. 2021;23(suppl 1):50-62.
6. Apovian CM, Aronne LJ, Bessesen DH, et al.; Endocrine Society . Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362.
7. Srivastava G, Apovian CM. Current pharmacotherapy for obesity. Nat Rev Endocrinol. 2018;14(1):12-24.
8. Bays HE, Fitch A, Christensen S, Burridge K, Tondt J. Anti-obesity medications and investigational agents: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars. 2022;2:100018.
9. Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017;3(1):3-14.
10. Calderon G, Gonzalez-Izundegui D, Shan KL, et al.. Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. Int J Obes (Lond). 2022;46(3):555-563.
11. Yanovski SZ, Yanovski JA. Progress in pharmacotherapy for obesity. JAMA. 2021;326(2):129-130.
12. Miles KE, Kerr JL. Semaglutide for the treatment of type 2 diabetes mellitus. J Pharm Technol. 2018;34(6):281-289.
13. Canadian Agency for Drugs and Technologies in Health . CADTH common drug review: pharmacoeconomic review report: semaglutide (Ozempic) (Novo Nordisk Canada Inc.). 2019. Accessed October 27, 2023. https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/sr0594-ozempic-pharmacoeconomic-review-report.pdf
14. U.S. Food and Drug Administration . FDA approves new drug treatment for chronic weight management, first since 2014. June 4, 2021. Accessed October 27, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
15. Rubino DM, Greenway FL, Khalid U, et al.; STEP 8 Investigators . Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138-150.
16. Kushner RF, Calanna S, Davies M, et al.. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050-1061.
17. Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity. Gastroenterology. 2002;123(3):882-932.
18. Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group . Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
19. Rubino D, Abrahamsson N, Davies M, et al.; STEP 4 Investigators . Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425.
20. Wadden TA, Bailey TS, Billings LK, et al.; STEP 3 Investigators . Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403-1413.
21. World Health Orgnization. Obesity and overweight; 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed October 27, 2023.
22. Adams K, Schatzkin A, Harris TB. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355(8):763–778.
23. James PT, Rigby N, Leach R, NRRL. International Obesity Task Force. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil. 2004;11(1):3–8.
24. Lakka TA, Lakka H-M, Salonen R, Kaplan GA, Salonen JT. Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men. Atherosclerosis. 2001;154(2):497–504.
25. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875–880.
26. Klein H, Asseo K, Karni N, et al. Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients. Clin Microbiol Infect. 2021;27(5):769–774.
27. Koch CA, Bartel MJ, Weinberg DS. Possible Mechanisms: hyperinsulinemia and Endocrine Disrupting Chemicals. Dtsch Arztebl Int. 2021;118(15):271.
28. Lasikiewicz N, Myrissa K, Hoyland A, Lawton CL. Psychological benefits of weight loss following behavioural and/or dietary weight loss interventions. A systematic research review. Appetite. 2014;72:123–137.
29. Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation. 2002;105(7):804–809.
30. Arranz LI, Rafecas M, Alegre C. Effects of obesity on function and quality of life in chronic pain conditions. Curr Rheumatol Rep. 2014;16.
31. Fujioka K. Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes Obes Metab. 2015;17(11):1021–1032.
32. Kovács E, Hunsberger M, Reisch L, et al. Adherence to combined lifestyle factors and their contribution to obesity in the IDEFICS study. Obes Rev. 2015;16:138–150.
33. Dessify B, Wood C, Parker D, Carmichael D, Petrick A, Daouadi M. Is there a Role for Bariatric Surgery in Patients with Severe Obesity in Type 1 Diabetes Mellitus? Surg Obes Relat Dis. 2021;18(2):177–181.
34. Hagström H, Ekstedt M, Olbers T, Peltonen M, Carlsson L. Bariatric Surgery Versus Standard Obesity Treatment and the Risk of Severe Liver Disease: data From the Swedish Obese Subjects Study. Clin Gastroenterol Hepatol. 2020;4:854.
35. Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab. 2021;46:101090.